FDL 169
Alternative Names: CFTR-corrector; FDL169Latest Information Update: 28 Jan 2021
Price :
$50 *
At a glance
- Originator Flatley Discovery Lab
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cystic fibrosis
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in United Kingdom (Sublingual, Tablet)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Australia (PO)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Czech Republic (PO)